title: Reply to S. Iwase et al.
authors.affiliation: University Hospital Mannheim, Mannheim ralf.hofheinz@umm.de.
authors.forename: Ralf-Dieter
authors.initials: RD
authors.lastname: Hofheinz
authors.affiliation: Hochschule für Technik und Wirtschaft des Saarlandes, Saarbrücken, Germany.
authors.forename: Iris
authors.initials: I
authors.lastname: Burkholder
authors.affiliation: University of Heidelberg, Heidelberg, Germany.
authors.forename: Andreas
authors.initials: A
authors.lastname: Schneeweiss
mesh_terms: D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects*; D000975:Antioxidants / Q000008:administration & dosage*; D003841:Deoxycytidine / Q000031:analogs & derivatives*; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives*; D060831:Hand-Foot Syndrome / Q000517:prevention & control*; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage*; D008297:Male; D011322:Primary Prevention / Q000379:methods*; D011788:Quality of Life; D014508:Urea / Q000008:administration & dosage*
chemical_list: D000964:Antimetabolites, Antineoplastic; D000975:Antioxidants; D007641:Keratolytic Agents; D003841:Deoxycytidine; D014508:Urea; D005472:Fluorouracil